QUINCE THERAPEUTICS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.05 USD | -0.94% |
|
+5.37% | 0.00% |
| Apr. 01 | Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 26 | Transcript : Quince Therapeutics, Inc. - Special Call |
Financials (USD)
| Sales 2022 | - | Sales 2023 | - | Capitalization | 45.01M |
|---|---|---|---|---|---|
| Net income 2022 | -51M | Net income 2023 | -31M | EV / Sales 2022 | - |
| Net cash position 2022 | 89.73M | Net cash position 2023 | 61.24M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-0.41
x | P/E ratio 2023 |
-1.25
x | Employees | 32 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 82.94% |
More Fundamentals
* Assessed data
More news
Latest transcript on Quince Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +0.47% | ||
| 1 week | +5.37% | ||
| Current month | -0.94% | ||
| 1 month | -12.50% | ||
| 3 months | -17.32% | ||
| 6 months | +5.00% |
1 week
0.96
1.10
1 month
0.891.25
Current year
0.891.43
1 year
0.841.74
3 years
0.54121.98
5 years
0.54121.98
10 years
0.54121.98
| Managers | Title | Age | Since |
|---|---|---|---|
Dirk Thye
CEO | Chief Executive Officer | 54 | 22-05-18 |
Brendan Hannah
DFI | Director of Finance/CFO | 39 | 22-04-30 |
Charles Ryan
PSD | President | 60 | 23-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Una Ryan
BRD | Director/Board Member | 82 | 18-02-28 |
Luca Benatti
BRD | Director/Board Member | 63 | 23-10-22 |
Dirk Thye
CEO | Chief Executive Officer | 54 | 22-05-18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 1.05 | -0.94% | 11 362 |
| 24-04-22 | 1.06 | +0.95% | 57,652 |
| 24-04-19 | 1.05 | -0.94% | 97,247 |
| 24-04-18 | 1.06 | +6.00% | 80,582 |
| 24-04-17 | 1 | +0.35% | 107,929 |
Delayed Quote Nasdaq, April 23, 2024 at 10:13 am EDT
More quotes
Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patientâs own biology to deliver life-changing therapeutics to those living with rare diseases. The Companyâs asset, EryDex, is being developed for the treatment of a rare neurodegenerative disease, Ataxia-Telangiectasia (A-T). EryDex utilizes a technology platform for autologous intracellular drug encapsulation (AIDE). Its proprietary AIDE technology is designed to optimize the biodistribution of dexamethasone sodium phosphate (DSP; a pro-drug) by using an A-T patientâs own red blood cells to deliver the sustained therapeutic over a once-monthly treatment period. The Company is also designed to allow for the chronic administration of the therapeutic. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules, as well as biologics. The Company also intends to investigate additional potential applications of the AIDE technology platform.
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 45.81M | |
| +1.79% | 42.11B | |
| +49.28% | 40.08B | |
| +7.54% | 40B | |
| -11.32% | 26.87B | |
| +6.70% | 24.58B | |
| -21.89% | 18.44B | |
| +1.34% | 11.94B | |
| +21.04% | 11.66B | |
| +7.92% | 11.01B |
- Stock Market
- Equities
- QNCX Stock
